Rigel Pharmaceuticals, Inc.

295 articles with Rigel Pharmaceuticals, Inc.

• Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

  2/28/2019

  Rigel Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.

• Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results

  2/21/2019

  Rigel Pharmaceuticals, Inc. announced that it will report its fourth quarter and year end 2018 financial results after market close on Thursday, February 28, 2019.

• Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

  1/23/2019

  Grifols gains exclusive rights to fostamatinib in all potential indications in Europe and Turkey

• Rigel Pharmaceuticals Provides Business Update

  1/7/2019

  Reports 1,794 total bottles of TAVALISSE™ (fostamatinib disodium hexahydrate) sold in 2018

• Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference

  1/3/2019

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 11:00am PT in San Francisco, CA.

• Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City

  12/5/2018

  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's executive vice president and chief financial officer, is scheduled to present a company overview at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

• Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update

  11/6/2018

  Reports TAVALISSE™ (fostamatinib disodium hexahydrate) net product sales of $4.9 million

• Rigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition

  11/1/2018

  Data related to fostamatinib accepted for oral presentation and two poster presentations

• Rigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results

  10/30/2018

  Rigel Pharmaceuticals, Inc. today announced that it will report its third quarter 2018 financial results after market close on Tuesday, November 6, 2018. 

• Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries

  10/29/2018

  Kissei gains exclusive rights to fostamatinib in all current and potential indications in Japan and other Asian countries.

• Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients

  10/11/2018

  First SYK inhibitor for the treatment of adult chronic ITP

• Rigel to Present at the Cantor Global Healthcare Conference

  9/24/2018

  The company's president and chief executive officer is scheduled to present a company overview at the Cantor Global Healthcare Conference in New York City on Wednesday, October 3, 2018 at 1:05pm EDT.

• Rigel to Present at the 20th Annual Global Investment Conference in New York City

  8/29/2018

  Rigel Pharmaceuticals, Inc. today announced that Dean Schorno, the company's executive vice president and chief financial officer, is scheduled to present a company overview at the 20th Annual Rodman & Renshaw Global Investment Conference

• Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update

  8/8/2018

  $1.8 Million in Net Product Sales for TAVALISSE™ (fostamatinib disodium hexahydrate)

• Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results

  8/1/2018

  Rigel Pharmaceuticals, Inc. announced that it will report its second quarter 2018 financial results after market close on Wednesday, August 8, 2018.

• Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

  6/26/2018

  Rigel selected R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) preclinical development program, for human clinical trials.

• US Bioservices Selected by Rigel Pharmaceuticals, Inc. to Dispense TAVALISSE™ (fostamatinib disodium hexahydrate) Tablets

  6/18/2018

  New therapy FDA-approved for adult patients with chronic immune thrombocytopenia

• Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA

  6/12/2018

  Rigel Pharmaceuticals, Inc. announced that it will be presenting an oral presentation on the Phase 2 Stage 1 interim results for fostamatinib in patients with warm antibody hemolytic anemia (AIHA) at the 23rd Congress of the European Hematology Association (EHA)

• Rigel to Present at Jefferies 2018 Global Healthcare Conference

  5/31/2018

  Rigel Pharmaceuticals, Inc. announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Global Healthcare Conference.

• Rigel Appoints Dean Schorno as Chief Financial Officer

  5/30/2018

  Rigel Pharmaceuticals, Inc. today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO).